EG628359 Inhibitors
Gm6871, a predicted gene, emerges as a key player in cellular processes by virtue of its predicted functions, which include enabling DNA-binding transcription factor activity specific to RNA polymerase II and exhibiting sequence-specific DNA binding activity within the cis-regulatory regions. Its predicted activity in the nucleus further emphasizes its involvement in the intricate regulation of transcription by RNA polymerase II. The functional context suggests a critical role for Gm6871 in orchestrating gene expression, specifically influencing the activity of RNA polymerase II during transcriptional processes. As a potential transcription factor, Gm6871 likely participates in the precise control and modulation of gene expression within the nucleus, contributing to the complex regulatory network that governs cellular functions.
Exploring the mechanisms of inhibiting Gm6871 unveils a multifaceted landscape involving a diverse array of chemical inhibitors. These inhibitors act through various pathways, directly or indirectly influencing the predicted functions of Gm6871. Direct inhibition may occur through interference with RNA polymerase II, such as by RNA polymerase II inhibitors like Actinomycin D and α-Amanitin. Indirect inhibition involves disrupting DNA-related processes, exemplified by DNA crosslinking agents like Cisplatin or topoisomerase inhibitors like Camptothecin. Additionally, the modulation of critical cellular processes, such as cyclin-dependent kinase (CDK) activity by inhibitors like Flavopiridol or DRB, indirectly impacts the phosphorylation events crucial for RNA polymerase II function. The exploration of these mechanisms not only sheds light on potential ways to inhibit Gm6871 but also provides insights into the intricate regulatory networks that govern its predicted transcriptional functions. As an integral part of cellular transcriptional machinery, the inhibition of Gm6871 unravels the complex interplay between transcription factors, polymerases, and DNA dynamics, contributing to a deeper understanding of its role in cellular processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D, a DNA intercalator, directly inhibits transcription by RNA polymerase II. By intercalating into DNA, it disrupts the progression of RNA polymerase II, hindering the gene expression process and indirectly inhibiting the predicted DNA-binding transcription factor activity of Gm6871. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
α-Amanitin, a potent RNA polymerase II inhibitor, directly hinders transcription by RNA polymerase II. Its binding to RNA polymerase II prevents RNA synthesis, subsequently impacting Gm6871's predicted role in RNA polymerase II-specific transcription factor activity and cis-regulatory region sequence-specific DNA binding. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol, a CDK inhibitor, directly targets cyclin-dependent kinases involved in transcription regulation. By inhibiting CDKs, it disrupts the phosphorylation of RNA polymerase II, interfering with transcription and indirectly affecting Gm6871's predicted DNA-binding transcription factor activity and cis-regulatory region sequence-specific DNA binding. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin, a DNA crosslinking agent, directly induces DNA damage. This damage can interfere with the binding of transcription factors to specific DNA sequences, potentially affecting Gm6871's predicted RNA polymerase II-specific transcription factor activity and cis-regulatory region sequence-specific DNA binding. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide, an inhibitor of RNA polymerase II, directly hampers the activity of this enzyme. By inhibiting RNA synthesis, it indirectly interferes with Gm6871's predicted DNA-binding transcription factor activity and cis-regulatory region sequence-specific DNA binding, disrupting the normal course of gene expression. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB), a CDK9 inhibitor, directly targets a kinase involved in transcription. By inhibiting CDK9, it disrupts the phosphorylation of RNA polymerase II, impacting transcription and indirectly influencing Gm6871's predicted DNA-binding transcription factor and cis-regulatory region sequence-specific DNA binding activities. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Camptothecin, a topoisomerase I inhibitor, directly interferes with DNA topology. By inhibiting topoisomerase I, it induces DNA damage, potentially affecting Gm6871's predicted RNA polymerase II-specific transcription factor activity and cis-regulatory region sequence-specific DNA binding. | ||||||
Fludarabine | 21679-14-1 | sc-204755 sc-204755A | 5 mg 25 mg | $58.00 $204.00 | 15 | |
Fludarabine, a nucleoside analog, directly impacts DNA synthesis. By incorporating into DNA strands, it interferes with transcription and replication processes, indirectly influencing Gm6871's predicted RNA polymerase II-specific transcription factor activity and cis-regulatory region sequence-specific DNA binding. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
Fluorouracil, a thymidylate synthase inhibitor, directly interferes with nucleotide synthesis. By disrupting the supply of nucleotides, it indirectly impacts DNA synthesis and transcription, potentially influencing Gm6871's predicted RNA polymerase II-specific transcription factor activity and cis-regulatory region sequence-specific DNA binding. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Etoposide, a topoisomerase II inhibitor, directly disrupts DNA topology. By inhibiting topoisomerase II, it induces DNA damage, potentially influencing Gm6871's predicted RNA polymerase II-specific transcription factor activity and cis-regulatory region sequence-specific DNA binding. | ||||||